Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)
China · Delayed Price · Currency is CNY 51.46
+2.58 (5.28%)
Feb 3, 2026, 3:00 PM CST
SHA:688091 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 246.55 | 173.03 | 359.75 | 235.7 | 4.08 | - |
Other Revenue | 0.51 | 0.51 | 0.51 | 0.25 | - | - |
| 247.05 | 173.53 | 360.25 | 235.96 | 4.08 | - | |
Revenue Growth (YoY) | -1.44% | -51.83% | 52.68% | 5686.76% | - | - |
Cost of Revenue | 44.78 | 13.34 | 23.62 | 16.97 | 0.3 | - |
Gross Profit | 202.27 | 160.2 | 336.63 | 218.99 | 3.78 | - |
Selling, General & Admin | 135.29 | 143.05 | 147.57 | 98.64 | 17.29 | 12.09 |
Research & Development | 66.36 | 37.2 | 22.45 | 7.93 | 13.24 | 17.89 |
Other Operating Expenses | 2.34 | 1.01 | 1.61 | 0.9 | 0.03 | 0.04 |
Operating Expenses | 203.5 | 176.21 | 177.07 | 109.51 | 30.77 | 30.03 |
Operating Income | -1.23 | -16.01 | 159.57 | 109.48 | -26.99 | -30.03 |
Interest Expense | - | -0.7 | -0.27 | - | -0.59 | -0.01 |
Interest & Investment Income | 15.99 | 25.04 | 34.35 | 30.32 | 8.6 | 5.72 |
Other Non Operating Income (Expenses) | 3.24 | -0.09 | -0.05 | -0 | -0.02 | -0.02 |
EBT Excluding Unusual Items | 18.01 | 8.24 | 193.59 | 139.79 | -19 | -24.34 |
Gain (Loss) on Sale of Investments | 0.92 | - | 0.42 | 0.9 | 3.25 | 0.11 |
Gain (Loss) on Sale of Assets | -0 | -0 | - | - | - | - |
Asset Writedown | -0.01 | - | - | - | - | - |
Other Unusual Items | -2.89 | -3.42 | -7.11 | 8.87 | 6.47 | 2.38 |
Pretax Income | 16.04 | 4.82 | 186.9 | 149.56 | -9.28 | -21.85 |
Income Tax Expense | -6.92 | -2.16 | 25.35 | 6.71 | -5.28 | - |
Net Income | 22.96 | 6.98 | 161.55 | 142.85 | -4 | -21.85 |
Net Income to Common | 22.96 | 6.98 | 161.55 | 142.85 | -4 | -21.85 |
Net Income Growth | -64.99% | -95.68% | 13.09% | - | - | - |
Shares Outstanding (Basic) | 232 | 233 | 158 | 206 | 156 | 152 |
Shares Outstanding (Diluted) | 232 | 233 | 158 | 206 | 156 | 152 |
Shares Change (YoY) | 46.62% | 46.80% | -23.24% | 32.68% | 2.51% | 8.64% |
EPS (Basic) | 0.10 | 0.03 | 1.02 | 0.69 | -0.03 | -0.14 |
EPS (Diluted) | 0.10 | 0.03 | 1.02 | 0.69 | -0.03 | -0.14 |
EPS Growth | -76.13% | -97.06% | 47.34% | - | - | - |
Free Cash Flow | -137.34 | -40.6 | 77.77 | 74.9 | -51.93 | -25.22 |
Free Cash Flow Per Share | -0.59 | -0.17 | 0.49 | 0.36 | -0.33 | -0.17 |
Dividend Per Share | - | - | 0.031 | 0.210 | - | - |
Dividend Growth | - | - | -85.22% | - | - | - |
Gross Margin | 81.87% | 92.31% | 93.44% | 92.81% | 92.75% | - |
Operating Margin | -0.50% | -9.23% | 44.29% | 46.40% | -661.96% | - |
Profit Margin | 9.29% | 4.02% | 44.84% | 60.54% | -98.03% | - |
Free Cash Flow Margin | -55.59% | -23.40% | 21.59% | 31.74% | -1273.49% | - |
EBITDA | 12.4 | -4.85 | 167.45 | 115.91 | -20.4 | -23.86 |
EBITDA Margin | 5.02% | -2.79% | 46.48% | 49.12% | - | - |
D&A For EBITDA | 13.62 | 11.16 | 7.88 | 6.43 | 6.59 | 6.17 |
EBIT | -1.23 | -16.01 | 159.57 | 109.48 | -26.99 | -30.03 |
EBIT Margin | -0.50% | -9.23% | 44.29% | 46.40% | - | - |
Effective Tax Rate | - | - | 13.56% | 4.48% | - | - |
Revenue as Reported | 247.05 | 173.53 | 360.25 | 235.96 | 4.08 | - |
Advertising Expenses | - | - | - | - | 0.33 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.